In a significant medical advancement, researchers at a Gurugram-based institute have reported a major breakthrough in the treatment of children suffering from Sickle Cell Disease (SCD), a genetic blood disorder that affects the shape and function of red blood cells.

The institute’s clinical research team has developed a novel therapy protocol that combines gene-modified stem cell transplantation and targeted drug therapy, showing remarkable improvement in patient recovery rates and a reduction in painful episodes commonly associated with SCD.

According to lead researcher Dr. [Name], the treatment has demonstrated over 85% success rate in early trials, offering hope to thousands of children battling this life-threatening disease. The therapy not only minimizes disease symptoms but also shows potential in achieving long-term remission.

“Our approach focuses on repairing the defective gene responsible for sickle cell formation while enhancing the body’s ability to produce healthy hemoglobin,” said Representative. “The results have been both clinically significant and emotionally rewarding for patients and families.”

The study is being conducted in collaboration with leading pediatric hematology centres and is expected to undergo further validation through multicentric clinical trials across India.

Experts believe this development could pave the way for cost-effective and accessible SCD treatment options, especially for children in tribal and rural regions where the disease burden is high.

The institute also plans to seek approval from the Indian Council of Medical Research (ICMR) for large-scale implementation, marking a potential milestone in India’s fight against genetic blood disorders.